Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03269526 · ClinicalTrials.gov registry record · Phase 1
BATs Treatment for Pancreatic Cancer, Phase Ib/II
A Phase 1 study of Metastatic Pancreatic Adenocarcinoma and Locally Advanced Pancreatic Adenocarcinoma, sponsored by University of Virginia.
- Active
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT03269526 is a Phase 1 study of Metastatic Pancreatic Adenocarcinoma and Locally Advanced Pancreatic Adenocarcinoma that is active but no longer recruiting, run by University of Virginia. The registered enrollment target is 22 participants, below the 89-participant average among 37 other Metastatic Pancreatic Adenocarcinoma trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03269526, a Phase 1 study of Metastatic Pancreatic Adenocarcinoma and Locally Advanced Pancreatic Adenocarcinoma, is active but no longer recruiting, sponsored by University of Virginia.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This protocol will confirm toxicities and estimate the clinical efficacy of combining anti-CD3 x anti-EGFR bispecific antibody (EGFRBi) armed activated T cells (EGFR BATs) given to patients with locally advanced or metastatic pancreatic cancer who have received at least one dose of first line chemotherapy and may have responding, stable or progressive disease. Phase Ib will confirm a safe dose of 8 infusions, given twice weekly, of EGFR-BATs in 3 to 6 subjects. The phase II portion of the trial will test the clinical efficacy of this dose in 22 patients (including those in Phase Ib).
Conditions Studied
Interventions
- DRUG EGFR BATs after standard of care chemo
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-07-28 |
| Est. Completion | 2025-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03269526
The ClinicalTrials.gov registry entry for NCT03269526 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 37 other Metastatic Pancreatic Adenocarcinoma trials with a reported enrollment target (75% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which EGFR BATs after standard of care chemo is the first listed.
NCT03269526 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT03269526 about?
NCT03269526 is a clinical study titled "BATs Treatment for Pancreatic Cancer, Phase Ib/II". This protocol will confirm toxicities and estimate the clinical efficacy of combining anti-CD3 x anti-EGFR bispecific antibody (EGFRBi) armed activated T cells (EGFR BATs) given to patients with locally advanced or metastatic pancreatic cancer who have received at least one dose of first line chemot...
What is the current status of trial NCT03269526?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2017-07-28. Estimated completion is 2025-06-01.
What conditions does trial NCT03269526 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT03269526?
The interventions under investigation include: EGFR BATs after standard of care chemo (DRUG).
Who is sponsoring clinical trial NCT03269526?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03269526 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
RECRUITING · Phase 1
-
TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
RECRUITING · Phase 1
-
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
ACTIVE NOT RECRUITING · Phase 1
-
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Metastatic Pancreatic Adenocarcinoma
All registered trials for this condition
Locally Advanced Pancreatic Adenocarcinoma
All registered trials for this condition
Virginia
All trials with a study site in Virginia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.